ARTIVION, INC.
AORTNYSE
$25.06
↓ -2.6%Jul 17 close · end-of-day
Price
1Y↓ -20.4%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$1.2B
Enterprise Value
$1.4B
P/E
100.2
P/S
2.7
P/B
2.8
EV/EBITDA
23.1
PEG
—
FCF Yield
1.2%
Dividend Yield
—
Revenue (TTM)
$458.7M
Net Income (TTM)
$11.7M
Free Cash Flow (TTM)
$14.6M
Gross Margin
64.5%
Operating Margin
8.2%
Net Margin
2.5%
ROE
2.6%
ROIC
4.1%
Debt / Equity
0.5
Net Cash
-$159.6M
Return 1Y
-18.8%
Company profile
Artivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins. It also provides E-xtra design engineering systems for the treatment of aortic vascular diseases.
- CEO
- James P. Mackin
- Sector
- Manufacturing
- Industry
- Medical Equipment
- Employees
- 1,300
- Headquarters
- Georgia
- Website
- artivion.com
Management & directors
- Green Andrew MSVP, Regulatory and Quality
- Holloway Jean FSVP, General Counsel
- Berry Lance AEVP, COO, CFO & Treasurer
- Davis John EChief Commercial Officer
- Horton AmyVP, Chief Accounting Officer
- Mackin James PPresident & CEO
- Stanton Marshall S.SVP, Clinical & MD Affair
Roles derived from SEC Form 4 filings.
Earnings
AORT Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$116.3M↑ +17.5%
Diluted EPS$0.03↓ -400.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $253.2M | $298.8M | $313.8M | $354.0M | $388.5M | $441.3M |
| Gross profit | $167.8M | $197.5M | $202.5M | $229.2M | $248.8M | $284.2M |
| Operating income | $2.4M | $8.1M | $6.2M | $5.7M | $38.9M | $33.7M |
| Net income | -$16.7M | -$14.8M | -$19.2M | -$30.7M | -$13.4M | $9.8M |
| Diluted EPS | -$0.44 | -$0.38 | -$0.48 | -$0.75 | -$0.32 | $0.21 |
| Operating cash flow | $12.4M | -$2.6M | -$5.2M | $18.8M | $22.2M | $39.9M |
| Free cash flow | $5.0M | -$15.7M | -$15.9M | $9.1M | $11.0M | $839,000.00 |
| Gross margin | 66.3% | 66.1% | 64.5% | 64.7% | 64.0% | 64.4% |
| Operating margin | 1.0% | 2.7% | 2.0% | 1.6% | 10.0% | 7.6% |
| Net margin | -6.6% | -5.0% | -6.1% | -8.7% | -3.4% | 2.2% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $98.0M | $95.8M | $97.3M | $99.0M | $113.0M | $113.4M | $116.0M | $116.3M |
| Gross profit | $63.3M | $61.0M | $61.5M | $63.6M | $73.1M | $74.4M | $73.1M | $75.4M |
| Operating income | $6.5M | $4.4M | $2.7M | $2.1M | $8.4M | $12.5M | $10.7M | $5.8M |
| Net income | -$2.1M | -$2.3M | -$16.5M | -$505,000.00 | $1.3M | $6.5M | $2.4M | $1.4M |
| Diluted EPS | -$0.05 | -$0.05 | -$0.40 | -$0.01 | $0.03 | $0.13 | $0.06 | $0.03 |
| Operating cash flow | $6.1M | $11.5M | $10.1M | -$17.0M | $15.0M | $22.3M | $19.6M | $1.2M |
| Free cash flow | $3.6M | $7.8M | $8.7M | -$20.6M | $11.7M | $17.7M | -$7.9M | -$6.8M |
| Gross margin | 64.6% | 63.7% | 63.2% | 64.2% | 64.7% | 65.6% | 63.1% | 64.9% |
| Operating margin | 6.6% | 4.6% | 2.7% | 2.2% | 7.4% | 11.1% | 9.2% | 5.0% |
| Net margin | -2.2% | -2.4% | -16.9% | -0.5% | 1.2% | 5.7% | 2.1% | 1.2% |
Company news
Jul 16, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-11 | GREEN ANDREW M· SVP, Regulatory and Quality | Sale | 30,000 | $20.69 | $620,820.00 | filing |
| 2026-06-11 | GREEN ANDREW M· SVP, Regulatory and Quality | Option exercise | 30,000 | $11.03 | $330,900.00 | filing |
| 2026-06-11 | GREEN ANDREW M· SVP, Regulatory and Quality | Sale | 14,001 | $20.71 | $289,918.71 | filing |
| 2026-06-11 | GREEN ANDREW M· SVP, Regulatory and Quality | Option exercise | 14,001 | $18.44 | $258,178.44 | filing |
| 2026-06-02 | SEMEDO ANTHONY B. | J | 6,325 | $0.00 | $0.00 | filing |
| 2026-06-02 | SEMEDO ANTHONY B. | J | 6,325 | $0.00 | $0.00 | filing |
| 2026-05-18 | BEVEVINO DANIEL J | Award | 7,576 | $0.00 | $0.00 | filing |
| 2026-05-18 | ACKERMAN THOMAS F | Award | 7,576 | $0.00 | $0.00 | filing |
| 2026-05-18 | Salveson Jon W | Award | 7,576 | $0.00 | $0.00 | filing |
| 2026-05-18 | Borgstrom Marna P | Award | 7,576 | $0.00 | $0.00 | filing |
| 2026-05-18 | SEMEDO ANTHONY B. | Award | 7,576 | $0.00 | $0.00 | filing |
| 2026-05-18 | Hoff Elizabeth A | Award | 7,576 | $0.00 | $0.00 | filing |
| 2026-05-18 | Burbank Jeffrey H | Award | 7,576 | $0.00 | $0.00 | filing |
| 2026-05-18 | Bullock James | Award | 7,576 | $0.00 | $0.00 | filing |
| 2026-05-14 | Borgstrom Marna P | Award | 7,850 | $0.00 | $0.00 | filing |
| 2026-03-04 | Holloway Jean F· SVP, General Counsel | Sale | 8,962 | $38.00 | $340,556.00 | filing |
| 2026-03-03 | Mackin James P· President & CEO | Sale | 17,887 | $37.78 | $675,692.16 | filing |
| 2026-03-03 | Berry Lance A· EVP, COO, CFO & Treasurer | Sale | 6,316 | $37.78 | $238,590.69 | filing |
| 2026-03-03 | Davis John E· Chief Commercial Officer | Sale | 4,573 | $37.78 | $172,747.82 | filing |
| 2026-03-03 | Holloway Jean F· SVP, General Counsel | Sale | 3,843 | $37.78 | $145,171.63 | filing |
| 2026-03-03 | Stanton Marshall S.· SVP, Clinical & MD Affair | Sale | 2,149 | $37.78 | $81,179.76 | filing |
| 2026-03-03 | Horton Amy· VP, Chief Accounting Officer | Sale | 901 | $37.78 | $34,035.82 | filing |
| 2026-03-02 | Mackin James P· President & CEO | Sale | 14,911 | $38.02 | $566,989.28 | filing |
| 2026-03-02 | Berry Lance A· EVP, COO, CFO & Treasurer | Sale | 5,178 | $38.02 | $196,892.93 | filing |
| 2026-03-02 | Davis John E· Chief Commercial Officer | Sale | 2,784 | $38.02 | $105,861.32 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.